Sutro Biopharma (DB:S09) - Stock Price, News & Analysis

S09 Stock Overview

Sutro Biopharma, Inc. operates as a clinical-stage oncology company.

S09 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Revenue is forecast to grow 27.45% per year

Risk Analysis

Highly volatile share price over the past 3 months

Shareholders have been diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years

Sutro Biopharma, Inc. Competitors

Heidelberg Pharma

XTRA:HPHA

€141.7m

Formycon

XTRA:FYB

€690.5m

Biotest

XTRA:BIO3

€1.4b

Medigene

XTRA:MDG1

€42.2m

Price History & Performance

Summary of all time highs, changes and price drops for Sutro Biopharma
Historical stock prices
Current Share Price	US$3.42
52 Week High	US$5.45
52 Week Low	US$1.91
Beta	0.98
1 Month Change	12.50%
3 Month Change	-17.39%
1 Year Change	-16.99%
3 Year Change	-79.64%
5 Year Change	-61.36%
Change since IPO	-72.01%

Recent updates

Shareholder Returns

	S09	DE Biotechs	DE Market
7D	-4.5%	-3.1%	1.8%
1Y	-17.0%	-22.4%	2.2%

Return vs Industry: S09 exceeded the German Biotechs industry which returned -22.4% over the past year.

Return vs Market: S09 underperformed the German Market which returned 2.2% over the past year.

Price Volatility

Is S09's price volatile compared to industry and market?
S09 volatility
S09 Average Weekly Movement	14.1%
Biotechs Industry Average Movement	5.0%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.1%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: S09's share price has been volatile over the past 3 months.

Volatility Over Time: S09's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
2003	302	Bill Newell	www.sutrobio.com

Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.

Sutro Biopharma, Inc. Fundamentals Summary

How do Sutro Biopharma's earnings and revenue compare to its market cap?
S09 fundamental statistics
Market cap	€267.37m
Earnings (TTM)	-€99.79m
Revenue (TTM)	€143.65m

1.7x

P/S Ratio

-2.5x

P/E Ratio

Is S09 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
S09 income statement (TTM)
Revenue	US$153.73m
Cost of Revenue	US$180.43m
Gross Profit	-US$26.69m
Other Expenses	US$80.10m
Earnings	-US$106.79m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-1.39
Gross Margin	-17.36%
Net Profit Margin	-69.47%
Debt/Equity Ratio	2.7%

How did S09 perform over the long term?

See historical performance and comparison

S09 Stock Overview

Rewards

Risk Analysis

Sutro Biopharma, Inc. Competitors

XTRA:HPHA

€141.7m

XTRA:FYB

€690.5m

XTRA:BIO3

€1.4b

XTRA:MDG1

€42.2m

Price History & Performance

Recent News & Updates

Sutro Biopharma, Inc. has completed a Follow-on Equity Offering in the amount of $74.999998 million.

Sutro Biopharma, Inc. has filed a Follow-on Equity Offering in the amount of $74.999998 million.

Full year 2023 earnings released: US$1.78 loss per share (vs US$2.35 loss in FY 2022)

Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRa-Targeting ADC

Sutro Biopharma, Inc. Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023

Sutro Biopharma, Inc Appoints Jane Chung as President and Chief Operating Officer

Recent updates

Sutro Biopharma, Inc. has completed a Follow-on Equity Offering in the amount of $74.999998 million.

Sutro Biopharma, Inc. has filed a Follow-on Equity Offering in the amount of $74.999998 million.

Full year 2023 earnings released: US$1.78 loss per share (vs US$2.35 loss in FY 2022)

Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRa-Targeting ADC

Sutro Biopharma, Inc. Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023

Sutro Biopharma, Inc Appoints Jane Chung as President and Chief Operating Officer

Third quarter 2023 earnings released: US$0.81 loss per share (vs US$0.37 loss in 3Q 2022)

Sutro Biopharma Announces Presentation of Data for Luveltamab Tazevibulin (luvelta) from the Phase 1 Dose-Expansion Study in Endometrial Cancers At ESMO 2023

Sutro Biopharma, Inc. Appoints Hans Peter Gerber as Chief Scientific Officer

Chief Business Officer recently sold €67k worth of stock

Second quarter 2023 earnings released: US$0.64 loss per share (vs US$0.55 loss in 2Q 2022)

First quarter 2023 earnings released: US$0.85 loss per share (vs US$0.84 loss in 1Q 2022)

Full year 2022 earnings released: US$2.35 loss per share (vs US$2.29 loss in FY 2021)

Sutro Biopharma, Inc. Announces Results from Phase 1 Dose-Expansion Study of STRO-002

Sutro Biopharma, Inc. Announces Presentation of STRO-002 Data from the Compassionate Use Program in Pediatric Patients with Relapsed/Refractory CBF/GLIS AML at ASH 2022

Third quarter 2022 earnings released: US$0.37 loss per share (vs US$0.67 loss in 3Q 2021)

Sutro Biopharma, Inc. Announces Departure of Arturo Molina as Chief Medical Officer

Second quarter 2022 earnings released: US$0.55 loss per share (vs US$0.13 loss in 2Q 2021)

High number of new directors

Sutro Biopharma, Inc.(NasdaqGM:STRO) dropped from Russell 2000 Growth Index

High number of new directors

First quarter 2022 earnings released: US$0.84 loss per share (vs US$0.66 loss in 1Q 2021)

Sutro Biopharma, Inc., Annual General Meeting, Jun 06, 2022

Sutro Biopharma, Inc. Presents Nonclinical Data for Antibody-Drug Conjugate STRO-002 at the AACR Annual Meeting 2022

CEO & Director recently bought €71k worth of stock

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Sutro Biopharma Announces Interim Data from Dose-Expansion Cohort of STRO-002 Phase 1 Study for Patients with Advanced Ovarian Cancer

High number of new directors

Sutro Biopharma, Inc. Announces Company Kol Virtual Event to Provide Interim Dose Expansion Data for Antibody-Drug Conjugate Program Stro-002 for Treatment of Advanced Ovarian Cancer

Fred Hutchinson Cancer Research Center, in Partnership with Sutro Biopharma, to Present At American Society of Hematology Annual Meeting 2021

Third quarter 2021 earnings released: US$0.67 loss per share (vs US$0.47 profit in 3Q 2020)

Second quarter 2021 earnings released: US$0.13 loss per share (vs US$1.00 profit in 2Q 2020)

Sutro Biopharma Announces Additional Data for Dose-Escalation Phase 1 Study of STRO-002 to Be Presented At ASCO 2021

Forecast to breakeven in 2025

First quarter 2021 earnings released: US$6.61 loss per share (vs US$0.84 loss in 1Q 2020)

Full year 2020 earnings released: US$0.99 loss per share (vs US$2.43 loss in FY 2019)

Investor sentiment deteriorated over the past week

Sutro Biopharma Announces First Patient Dosed in the Dose-Expansion Study of STRO-002 in Patients with Ovarian Cancer

New 90-day high: €21.00

Investor sentiment improved over the past week

Sutro Biopharma Announces Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian Cancer

Market bids up stock over the past week

New 90-day high: €18.60

Sutro Biopharma Announces Appointment of Jon M. Wigginton to Board of Directors

Sutro Biopharma, Inc. Appoints Annie Chang as Head of Investor Relations

New 90-day high: €14.30

Market bids up stock over the past week

Revenue beats expectations

Third quarter 2020 earnings released: EPS US$0.46

New 90-day high: €11.10

New 90-day high - €10.00

Shareholder Returns

Price Volatility

About the Company

Sutro Biopharma, Inc. Fundamentals Summary

1.7x

-2.5x

Earnings & Revenue